[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Pérez Martínez A, Contra T, Scaglione C, Díaz Pérez MA, Madero López L: [Topotecan for pediatric patients with resistant and recurrent solid tumors]. An Pediatr (Barc); 2003 Aug;59(2):143-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topotecan for pediatric patients with resistant and recurrent solid tumors].
  • [Transliterated title] Topotecán en el tratamiento de niños con tumores sólidos refractarios o recidivantes.
  • BACKGROUND: Topotecan is a cytotoxic drug isolated from the Camptotheca acuminata tree (from China).
  • It is able to block the enzyme DNA topoisomerase I and has recently been used in the treatment of pediatric cancer.
  • OBJECTIVES: To evaluate our preliminary experience with topotecan in the second line treatment of refractory solid tumors in the pediatric age group.
  • PATIENTS AND MEHTODS: We performed a retrospective study of 10 patients with various recurrent solid tumors resistant to first line treatment who were treated with topotecan alone or in association with other chemotherapeutic agents.
  • RESULTS: Ten patients with recurrent solid tumors or tumors that were refractory to conventional treatment (two neuroblastomas, three rhabdomyosarcoma, two PNET/Ewing's sarcoma, one anaplastic astrocytoma, one soft tissue sarcoma and one synovial sarcoma) were included.
  • CONCLUSIONS: In our experience, topotecan is beneficial in some refractory or recurrent solid tumors, especially neuroblastomas and soft tissue sarcomas.
  • Patients with a complete response to topotecan could benefit from high-dose chemotherapy and autologous stem cell rescue therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Topotecan / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Infant. Male. Neoplasm Staging. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12882743.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


2. Nishiyama N, Iwata T, Izumi N, Tsukioka T, Nagano K, Suehiro S: Aggressive repeat surgery for a recurrent synovial sarcoma in the pleura. Ann Thorac Cardiovasc Surg; 2009 Feb;15(1):46-9
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive repeat surgery for a recurrent synovial sarcoma in the pleura.
  • Pleural synovial sarcomas are an extremely rare disease entity, and only 21 surgical cases, including this one, have been reported.
  • We present a case of synovial sarcoma that underwent pneumonectomy for a recurrence of the disease.
  • A 31-year-old female, who in June 2005 had undergone surgical resection of a monophasic synovial sarcoma in the left pleural cavity combined with the affected left diaphragm, was admitted to our hospital in January 2007 and underwent chemotherapy with ifosfamide, pirarubicin, and methotrexate for a recurrent synovial sarcoma in the left pleural cavity.
  • The chest computed tomography revealed multiple tumors in the left pleura, and the tumors increased rapidly to occupy the left hemithorax.
  • No other recurrent sites were found, and she underwent tumor resection combined with the entire left lung in March 2007.
  • Pathological examination revealed dense proliferation of atypical spindle cells, the same findings as in the initial operation, and a diagnosis of synovial sarcoma was made.
  • External radiation therapy up to 60 Gray was given to the tumor remaining around the descending aorta.
  • She is now ambulatory without evidence of recurrent disease at 6 months after the second operation and 27 months after the initial surgery.
  • Although optimal strategies for synovial sarcoma have yet to be established, aggressive repeat surgery could be considered in selected cases even when response to chemotherapy is insufficient and complete resection is difficult.
  • [MeSH-major] Neoplasm Recurrence, Local. Pleural Neoplasms / surgery. Pneumonectomy. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Radiotherapy, Adjuvant. Reoperation. Thoracotomy. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262450.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Sobel E, Giorgini R, Oropeza R, Bapat K, Richardson H: Limb salvage in recurrent synovial sarcoma of the right ankle and lower leg. J Am Podiatr Med Assoc; 2002 Feb;92(2):90-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage in recurrent synovial sarcoma of the right ankle and lower leg.
  • Synovial sarcoma of the extremities represents 7% of all soft-tissue sarcomas.
  • This article presents the case of a patient who was treated for a synovial sarcoma of the lateral aspect of the distal lower leg extending to the ankle and involving the fibular bone.
  • The patient underwent a wide excision of the tumor, including the fibular bone, followed by radiation and chemotherapy, rather than undergo an amputation of the right leg.
  • [MeSH-major] Bone Neoplasms / therapy. Limb Salvage / methods. Neoplasm Recurrence, Local / therapy. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adult. Ankle. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Leg. Osteotomy / methods. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11847260.001).
  • [ISSN] 8750-7315
  • [Journal-full-title] Journal of the American Podiatric Medical Association
  • [ISO-abbreviation] J Am Podiatr Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Hohenberger P, Tunn PU: Isolated limb perfusion with rhTNF-alpha and melphalan for locally recurrent childhood synovial sarcoma of the limb. J Pediatr Hematol Oncol; 2003 Nov;25(11):905-9
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with rhTNF-alpha and melphalan for locally recurrent childhood synovial sarcoma of the limb.
  • The use of isolated, hyperthermic limb perfusion (ILP) for locally recurrent synovial sarcoma in two children is reported.
  • Six weeks later, the former tumor bed and irradiation field was excised together with myocutaneous flap reconstruction for soft tissue coverage.
  • Six months after completion of treatment, near-perfect limb function was determined by general clinical assessment and validated scoring systems.
  • ILP, an accepted technique in treating adult extremity sarcoma, might also be of value in children as a means of limb-saving therapy.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Melphalan / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Sarcoma, Synovial / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14608203.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


5. Srivastava A, Nielsen PG, Dal Cin P, Rosenberg AE: Monophasic synovial sarcoma of the liver. Arch Pathol Lab Med; 2005 Aug;129(8):1047-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monophasic synovial sarcoma of the liver.
  • We report a hepatic monophasic synovial sarcoma in a 60-year-old woman who presented with right upper quadrant pain subsequent to an intrahepatic bleed from a highly vascular tumor mass.
  • The morphologic, immunophenotypic, and cytogenetic findings (t(X;18)(p11.2;icq11.2)) were consistent with a monophasic synovial sarcoma.
  • Postoperative clinical evaluation of the extremities and a positron emission tomographic scan performed 4 weeks after surgery showed no evidence of recurrent or metastatic disease.
  • The patient was started on an aggressive 4-drug chemotherapy regimen, but died 3 months thereafter from widespread metastatic disease.
  • It would, however, be very unusual for a synovial sarcoma to present as an occult primary, and the negative radiologic workup 1 month after the partial hepatectomy also argues against this possibility.
  • The clinical presentation, radiographic findings, and subsequent course in this patient was therefore most consistent with a primary monophasic synovial sarcoma of the liver.
  • [MeSH-major] Liver Neoplasms / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Carcinoma, Hepatocellular / diagnosis. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 18. Chromosomes, Human, X. Diagnosis, Differential. Fatal Outcome. Female. Genetic Markers. Hemangiosarcoma / diagnosis. Hepatectomy. Humans. Middle Aged. Translocation, Genetic

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16048399.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


6. Katakura H, Fukuse T, Shiraishi I, Hayatsu E, Nishijo K, Toguchida J, Nakashima Y, Wada H: Mediastinal synovial sarcoma. Thorac Cardiovasc Surg; 2009 Apr;57(3):183-5
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal synovial sarcoma.
  • Synovial sarcoma of the mediastinum is a rare neoplasm that has overlapping histological and immunophenotypic features with other tumors in the differential diagnosis.
  • The doubling time of the main tumor was 11.8 days.
  • Reverse transcription-PCR confirmed the diagnosis of synovial sarcoma.
  • The patient rejected chemotherapy or radiation therapy, and had recurrent tumors only one month after the operation.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Sarcoma, Synovial / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Female. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Oncogene Proteins, Fusion / genetics. Palliative Care. Positron-Emission Tomography. Thoracotomy. Tomography, X-Ray Computed. Treatment Refusal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330763.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  •  go-up   go-down


7. Ford ME, Stevens R, Rosado-de-Christenson ML, Hall NC, Suster S: Rebound thymic hyperplasia after pneumonectomy and chemotherapy for primary synovial sarcoma. J Thorac Imaging; 2008 Aug;23(3):178-81
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rebound thymic hyperplasia after pneumonectomy and chemotherapy for primary synovial sarcoma.
  • Thymic hyperplasia occurs in a small proportion of patients receiving chemotherapy for various malignancies.
  • Fluorodeoxyglucose positron emission tomography-computed tomography is an important tool for staging malignant neoplasms.
  • We report a case of rebound thymic hyperplasia manifesting as a hypermetabolic mass on fluorodeoxyglucose positron emission tomography-computed tomography after pneumonectomy and chemotherapy for primary pulmonary synovial sarcoma.
  • We highlight the importance of recognizing the phenomenon of rebound thymic hyperplasia, as it can mimic residual or recurrent malignancy, especially in the setting of altered chest anatomy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pneumonectomy. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / surgery. Thymus Hyperplasia / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Humans. Ifosfamide / therapeutic use. Male. Neoplasm Recurrence, Local / complications. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • Genetic Alliance. consumer health - Thymic hyperplasia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728544.001).
  • [ISSN] 1536-0237
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


8. Deshmukh R, Mankin HJ, Singer S: Synovial sarcoma: the importance of size and location for survival. Clin Orthop Relat Res; 2004 Feb;(419):155-61
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma: the importance of size and location for survival.
  • A retrospective analysis was done on 135 consecutive patients with extremity and truncal synovial sarcomas seen at our institutions between 1961 and 1996.
  • Ninety-nine patients (73%) presented with a newly diagnosed localized primary sarcoma, nine patients (7%) presented with a locally recurrent sarcoma previously treated at another institution, and 27 patients (20%) presented with metastatic disease.
  • The overall survival for patients with localized primary and locally recurrent synovial sarcoma was 51% at 10 years.
  • Patients with localized synovial sarcomas less than 5 cm in longest diameter had a survival at 10 years of 88% compared with a 10-year survival of 38% and 8% for patients with sarcomas 5 to 10 cm and greater than 10 cm in longest diameter, respectively.
  • Distal location (hands and feet) and histologic grade also were statistically significant predictors of patient survival for localized synovial sarcoma on univariate analysis.
  • Primary tumor size and initial status at presentation were prognostic for survival and patients with synovial sarcomas larger than 5 cm or locally recurrent at presentation should be considered for more aggressive surgical and adjunctive radiotherapy or chemotherapy.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / pathology. Sarcoma, Synovial / mortality. Sarcoma, Synovial / pathology. Soft Tissue Neoplasms / mortality. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lower Extremity. Male. Middle Aged. Neoplasm Staging. Probability. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Upper Extremity

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15021147.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Van der Mieren G, Willems S, Sciot R, Dumez H, Van Oosterom A, Flameng W, Herijgers P: Pericardial synovial sarcoma: 14-year survival with multimodality therapy. Ann Thorac Surg; 2004 Sep;78(3):e41-2
Hazardous Substances Data Bank. DIMETHOATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial synovial sarcoma: 14-year survival with multimodality therapy.
  • We report a case of recurrent primary synovial sarcoma of the pericardium.
  • Because of the rarity of this entity, optimal therapy is unknown.
  • In this report, we present a case with five recurrences treated by a combination of surgery, chemotherapy, and radiotherapy.
  • The patient survives now for more than 14 years, the longest reported survival of a primary synovial sarcoma of the pericardium.
  • [MeSH-major] Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / surgery. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Dimethoate / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Isoquinolines / administration & dosage. Magnetic Resonance Imaging. Male. Neoplasm, Residual / drug therapy. Neoplasm, Residual / surgery. Palliative Care. Pericardium / radiography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15337081.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Isoquinolines; 0 / ecteinascidin 729; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide; W6U08B045O / Dimethoate
  •  go-up   go-down


10. Raney RB: Synovial sarcoma in young people: background, prognostic factors, and therapeutic questions. J Pediatr Hematol Oncol; 2005 Apr;27(4):207-11
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma in young people: background, prognostic factors, and therapeutic questions.
  • Synovial sarcoma represents 5% to 10% of all soft tissue sarcomas, with an estimated total of 800 new cases annually in the United States.
  • Anderson Cancer Center's Division of Pediatrics, St. Jude Children's Research Hospital, the German Cooperative Group, and Istituto Nazionale dei Tumori, Milan, found that, as in older people, tumor size larger than 5 cm, residual local tumor or metastases at diagnosis, and progressive or recurrent disease all portended a poor outcome.
  • There are currently no randomized studies of therapy for patients with synovial sarcoma, but such are needed to provide answers to the following questions: Is adjuvant chemotherapy useful in preventing recurrence in patients without visible residual disease after apparently complete surgical removal of localized tumor?
  • Should local radiation therapy be given to all patients who have had complete removal of the primary tumor with clear margins at the time of diagnosis?
  • [MeSH-major] Sarcoma, Synovial / pathology. Sarcoma, Synovial / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / pathology. Prognosis. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838392.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Mitsuhashi A, Nagai Y, Suzuka K, Yamazawa K, Nojima T, Nikaido T, Ishikura H, Matsui H, Shozu M: Primary synovial sarcoma in fallopian tube: case report and literature review. Int J Gynecol Pathol; 2007 Jan;26(1):34-7
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary synovial sarcoma in fallopian tube: case report and literature review.
  • Synovial sarcoma, a malignant mesenchymal neoplasm, occurs mostly near the joints of the extremities and occasionally outside the joint such as lung.
  • We report a case of soft tissue sarcoma arising in the fallopian tube origin that showed characteristic pathological appearance of biphasic synovial sarcoma.
  • Molecular analysis detected a fusion gene transcript of synovial sarcoma translocation (SYT) gene from chromosome 18 and synovial sarcoma X chromosome breakpoint 1 (SSX1) gene, which is believed to pathognomonic for synovial sarcoma of joint origin.
  • Recurrent abdominal tumor, observed at 12 month after the initial surgery and following chemotherapy using doxorubicin, cisplatin and ifosfamide, partially responded to chemotherapy using paclitaxel and carboplatin and, then, optimal surgery was performed.
  • This is the first report of a synovial sarcoma arising in the fallopian tube.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Sarcoma, Synovial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197895.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  • [Number-of-references] 12
  •  go-up   go-down


12. Ruka W, Rutkowski P, Falkowski S, Morysinski T, Nowecki ZI: Aggressive combined treatment of synovial sarcoma patients (pts) without distant metastases - single-center experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):9018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive combined treatment of synovial sarcoma patients (pts) without distant metastases - single-center experience.
  • : 9018 Background: Synovial sarcoma (SS) is a common type of high-grade soft tissue sarcoma (STS) with significant sensitivity to chemotherapy and poor prognosis (ASCO 1994, abst. 1645).
  • The aim of this single-center study was to analyze the results of intensive chemo- and radiotherapy treatment in pts with nonmetastastic (M0) SS.
  • METHODS: One hundred consecutive M0 SS pts (median age 32 years, range: 15-70; 23 pts had primary tumors and 77 pts - recurrences or scars after non-radical excision, 40% of tumors >5 cm) treated between 1995 and 2003 received chemotherapy (2 cycles of high-dose ifosfamide at dose of 11.9g/m<sup>2</sup>/7 days) and radiotherapy (20Gy over 5 days - 4Gy/fractions; fields contained the tumor - primary, recurrent or scar with drain sites and margins ≥ 5 cm) before surgical resection, followed by 4 cycles of postoperative multiagent chemotherapy (2 of ifosfamide - 11.9g/m<sup>2</sup>/7days and 2 of doxorubicin - 60mg/m<sup>2</sup> and cisplatin - 120mg/m<sup>2</sup>).
  • Median follow-up time was 21 months.
  • RESULTS: 92 pts received complete treatment, grade 3 and 4 toxicity (CTC 2.0) was observed in 27% of pts.
  • CONCLUSIONS: The encouraging results of intensive combined treatment of pts with localized SS indicate the 5-year survival rate of about 80% in this highly malignant type of STS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Tettoni K, Provenzi M, Fossati Bellani F, Carli M: Vinorelbine and low dose cyclophosphamide in pediatric sarcoma. A pilot study for the future European rhabdomyosarcoma protocol. J Clin Oncol; 2004 Jul 15;22(14_suppl):8540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vinorelbine and low dose cyclophosphamide in pediatric sarcoma. A pilot study for the future European rhabdomyosarcoma protocol.
  • Cancer 2002; 94: 3263) on the activity of vinorelbine (VNB) in rhabdomyosarcoma (RMS), we report the results of a pilot study aimed to define the dose of VNB in combination with low dose continuous oral cyclophosphamide (CTX) in patients with refractory or recurrent sarcomas.
  • The study was performed in the view of utilizing this treatment as maintenance therapy in the future European protocol for high risk RMS patients.
  • There was a median of 2 prior regimens (range 1-4); 5 patients previously received high dose chemotherapy with PBSC rescue and 12 prior radiotherapy.
  • Among 5 patients treated at dose level 4 (VNB 30 mg/m<sup>2</sup>) 2 dose limiting toxicities (grade 4 neutropenia) were observed in the first 2 cycles therefore a decision was made to enter 3 more patients at dose level 3.
  • Four patients were still on treatment after 5-10 cycles.
  • Partial responses were observed in 7/17 assessable patients: 3/8 RMS (2 embryonal, 1 alveolar), 1/1 clear cell sarcoma, 1/2 synovial sarcoma, 1/2 desmoplastic small round cell tumor, 1/1 osteosarcoma.
  • CONCLUSIONS: This combination appears to be feasible and active in relapsed sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013816.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Krieghoff B, Skuballa A, Leonhardt P, Mohr FW, Wittekind C, Bossert T, Achatzy R: [Primary synovial sarcoma of the lung - a rare tumor]. Zentralbl Chir; 2002 Aug;127(8):716-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary synovial sarcoma of the lung - a rare tumor].
  • [Transliterated title] Primäres Synovialsarkom der Lunge: ein sehr seltener Lungentumor.
  • We present a 26 year old patient with a primary malignant synovial sarcoma of the lung that was observed for more than one year by a general practitioner and a pulmologist.
  • Finally, because of recurrent hemoptysis a central tumor of mesenchymal origin of the left lower lobe was diagnosed by bronchoscopy.
  • In the postoperative course the patient underwent chemo-therapy, 6 cycles adriablastine/ifosfamid.
  • The patient refused further radio- or chemotherapy and died 14 months after the operation.
  • Because of the small number of cases therapeutic strategy conceptions do not exist.
  • [MeSH-major] Lung Neoplasms / surgery. Sarcoma, Synovial / surgery

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12200737.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Niwa H, Masuda S, Kobayashi C, Oda Y: Pulmonary synovial sarcoma with polypoid endobronchial growth: a case report, immunohistochemical and cytogenetic study. Pathol Int; 2004 Aug;54(8):611-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary synovial sarcoma with polypoid endobronchial growth: a case report, immunohistochemical and cytogenetic study.
  • A rare case of primary pulmonary synovial sarcoma with polypoid endobronchial growth in a 42-year-old Japanese woman is described.
  • Left upper sleeve lobectomy was performed for the polypoid tumor measuring 2.5 cm in the left major bronchus and the patient was treated with adjuvant chemotherapy.
  • Three years later, a recurrent tumor was discovered.
  • Recently, primary pulmonary synovial sarcoma is an increasingly recognized clinical entity; however, most of these tumors present as a parenchymal mass.
  • The present case is a unique example of primary synovial sarcoma of endobronchial polypoid type.
  • This case suggests that pulmonary synovial sarcoma might originate from bronchial submucosal stromal tissue.
  • [MeSH-major] Bronchi / pathology. Lung Neoplasms / pathology. Polyps / pathology. Sarcoma, Synovial / secondary

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15260852.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 0 / SS18 protein, human; 164289-47-8 / synovial sarcoma X breakpoint proteins
  •  go-up   go-down


16. Suppiah R, Wood L, Elson P, Budd GT: Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs; 2006 Nov;24(6):509-14
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
  • METHODS: Patients with advanced, recurrent, or metastatic STS, without prior chemotherapy, were enrolled in a dose escalation trial.
  • HISTOLOGY: leiomyosarcoma 10, spindle cell sarcoma 3, synovial sarcoma 2, angiosarcoma 1, fibrous histiocytoma 1, epitheliod hemangio-endothelioma 1, and 3 not specified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 1995 Oct;20(3):193-201 [8748009.001]
  • [Cites] Cancer. 1981 May 15;47(10):2422-9 [7272896.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Ter. 1998 Mar-Apr;149(2):121-5 [9780476.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2757-62 [7139566.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1087-94 [10572607.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1276-85 [8315425.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1281-8 [11697841.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2397-406 [12460784.001]
  • [Cites] Cancer. 1984 May 1;53(9):1825-32 [6367947.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • (PMID = 16791410.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


17. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • Most patients received chemotherapy in addition to bevacizumab.
  • Duration of bevacizumab therapy ranged from 1.5 to 23 months.
  • CONCLUSIONS: Bevacizumab seems to have a good acute safety profile and some antitumor activity in heavily pretreated children and young adults with recurrent solid tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


18. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer; 2008 Feb;50(2):254-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
  • Ewing sarcoma, osteosarcoma, neuroblastoma, desmoplastic small round cell, and synovial sarcomas often overexpress KIT or the PDGF receptor.
  • PROCEDURE: Patients less than 30 years of age with refractory or recurrent Ewing sarcoma, osteosarcoma, neuroblastoma, desmoplastic small round cell, synovial sarcomas or GIST were eligible.
  • Only one partial response was seen among 24 patients with Ewing sarcoma.
  • Hemorrhagic pleural effusions occurred in seven patients with pulmonary lesions, four of whom had progressive disease at the time of the hemorrhage.
  • CONCLUSION: Imatinib as a single agent at a dose of 440 mg/m(2)/day demonstrated little or no activity as a single agent in children with relapsed or refractory Ewing sarcoma, osteosarcoma, neuroblastoma, or desmoplastic small round cell tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasms / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Benzamides. Bone Neoplasms / drug therapy. Carcinoma, Small Cell / drug therapy. Child. Child, Preschool. Female. Gastrointestinal Stromal Tumors / drug therapy. Humans. Imatinib Mesylate. Male. Neuroblastoma / drug therapy. Osteosarcoma / drug therapy. Sarcoma, Ewing / drug therapy. Sarcoma, Synovial / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17262795.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA 98543
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


19. Issakov J, Merimsky O, Gutman M, Kollender Y, Lev-Chelouche D, Abu-Abid S, Lifschitz-Mercer B, Inbar M, Klausner JM, Meller I: Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations. Ann Surg Oncol; 2000 Mar;7(2):155-9
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
  • BACKGROUND: Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan was used as induction treatment in locally advanced extremity soft-tissue sarcomas for limb sparing surgery.
  • METHODS: Fresh tumor specimens of 27 high grade extensive soft-tissue sarcomas and 3 recurrent desmoid tumors of the extremities were collected 6 to 8 weeks after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha plus melphalan.
  • The specimens were studied for surgical margins, extent and type of tumor necrosis, lymph node involvement, perineural and vascular invasion, and the effects on adjacent normal tissues such as nerves, muscles, and blood vessels.
  • Some nonspecific changes were noted in the soft tissues around the mass.
  • The responsive types were malignant fibrous histiocytoma, followed by myxoid liposarcoma and synovial sarcoma.
  • The soft tissues adjacent to the tumor bed did not show major morphological changes.
  • No correlation was found between the histological changes and each of the following: the anatomical (upper vs. lower limb) or compartmental location of the tumor; whether the tumor was primary or recurrent; and the types of previous treatment (systemic chemotherapy or radiotherapy) and tumor size.
  • CONCLUSIONS: This is the first serial histological description of the effects of tumor necrosis factor-alpha and melphalan administered via hyperthermic isolated limb perfusion on the tumoral masses of limb soft-tissue sarcomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Melphalan / administration & dosage. Sarcoma / pathology. Soft Tissue Neoplasms / pathology. Tumor Necrosis Factor-alpha / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761796.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


20. Karnak I, Emin Senocak M, Kutluk T, Tanyel FC, Büyükpamukçu N: Pulmonary metastases in children: an analysis of surgical spectrum. Eur J Pediatr Surg; 2002 Jun;12(3):151-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary surgery is frequently used for the treatment of metastasis or nodules in children with various types of malignancies.
  • The primaries were osteosarcoma (n = 2), synovial sarcoma (n = 1), fibrosarcoma (n = 1), Ewing's sarcoma (n = 2), mesenchymal chondrosarcoma (n = 1), Wilms' tumour (n = 4), clear-cell sarcoma (n = 1), Hodgkin lymphoma (n = 3), hepatoblastoma (n = 1), hepatocellular carcinoma (n = 1) and haemangioendotheliosarcoma (n = 1).
  • Pulmonary metastases were encountered either at the time of initial diagnosis (22 %) or occurred within 6 months to 5 years.
  • The nodules contained tumour cells in most cases (n = 14) (78 %), mature nephrogenic elements (6 %) and no tumour tissue (16 %) in the remaining cases.
  • However, synovial sarcoma was encountered in metastasis in one case with fibrosarcoma primary.
  • Re-thoracotomy was performed in 22 % of cases for the recurrent lesion, which in only one case was a true local recurrence.
  • Therefore combined therapies such as chemotherapy and/or radiotherapy should be continued in the postoperative period.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Pneumonectomy. Retrospective Studies. Thoracotomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12101495.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement